Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, open-label study to observe the effect of SBRT and
immunotherapy combined with Bevacizumab or not in stage IV non-squamous non-small cell lung
cancer (NSCLC) with previously failed after chemotherapy.